[Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Schwab
M
M
Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie, Stuttgart.
Herrlinger
K
K
Schaeffeler
E
E
Stange
E F
EF
D001379:Azathioprine / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced; D015122:Mercaptopurine / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D008780:Methyltransferases / Q000097:blood / Q000235:genetics / Q000378:metabolism; D013329:Structure-Activity Relationship; D013866:Thioguanine / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D013866:Thioguanine; D001379:Azathioprine